Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | BCL6 | P41182 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5335551 | 0.84 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1L3MBTL1KMT2AMAPT | |
| SCHEMBL30577163 | 0.84 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1L3MBTL1KMT2AMAPT | |
| SCHEMBL1554935 | 0.84 | SMN1; SMN2 (0.40) | SMN1; SMN2ALDH1A1L3MBTL1KMT2AMAPT | |
| SCHEMBL16885200 | 0.81 | MAPT (0.40) | SMN1; SMN2ALDH1A1L3MBTL1KMT2AMAPT | |
| SCHEMBL12413633 | 0.78 | GLP1R (0.34) | SMN1; SMN2ALDH1A1RPS6KA5KDM4E | |
| SCHEMBL20909386 | 0.77 | ALDH1A1 (0.39) | SMN1; SMN2ALDH1A1L3MBTL1KMT2AMAPT | |
| SCHEMBL22681338 | 0.77 | CYP11B1 (0.31) | — | |
| SCHEMBL14997543 | 0.77 | PTGS1 (0.35) | POLB | |
| SCHEMBL18791406 | 0.76 | GCGR (0.33) | — | |
| SCHEMBL16248184 | 0.75 | S100A9 (0.33) | SMN1; SMN2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728223-B1 | CYCLOHEXYL ACID TRIAZOLE AZINES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2022-12-28 | — | — | EP | disclosed |
| US-11267800-B2 | Cyclohexyl acid triazole azines as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-03-08 | — | — | US | disclosed |
| US-20210230143-A1 | CYCLOHEXYL ACID TRIAZOLE AZINES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-29 | — | — | US | disclosed |
| US-20210230143-A1 | CYCLOHEXYL ACID TRIAZOLE AZINES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-29 | — | — | US | disclosed |
| US-20210179567-A1 | SYNTHESIS OF 1,4-DIAZASPIRO[5.5]UNDECAN-3-ONE | G1 THERAPEUTICS, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| EP-3728223-A1 | CYCLOHEXYL ACID TRIAZOLE AZINES AS LPA ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-2912041-B1 | TETRAHYDROPYRROLOTHIAZINE DERIVATIVES AS BACE INHIBITORS | LILLY CO ELI (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-2912041-B1 | TETRAHYDROPYRROLOTHIAZINE DERIVATIVES AS BACE INHIBITORS | LILLY CO ELI (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-2836495-B1 | TETRAHYDROPYRROLOTHIAZINE COMPOUNDS | LILLY CO ELI (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-2836495-B1 | TETRAHYDROPYRROLOTHIAZINE COMPOUNDS | LILLY CO ELI (US) | 2016-05-18 | — | — | EP | disclosed |
| US-8629270-B2 | Tetrahydropyrrolothiazine compounds | ELI LILLY AND COMPANY (US) | 2014-01-14 | — | — | US | disclosed |
| WO-2013151832-A1 | TETRAHYDROPYRROLOTHIAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013151832-A1 | TETRAHYDROPYRROLOTHIAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2013-10-10 | — | — | WO | disclosed |
| US-20130261111-A1 | TETRAHYDROPYRROLOTHIAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261111-A1 | TETRAHYDROPYRROLOTHIAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261111-A1 | TETRAHYDROPYRROLOTHIAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2013-10-03 | — | — | US | disclosed |
| US-8293729-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-8293729-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11267800-B2 | Cyclohexyl acid triazole azines as LPA antagonists | LPAR3, LPAR1, LPAR2 | SMN1; SMN2 4323/4885ALDH1A1 2244/4885L3MBTL1 4166/4885 |
| US-20210230143-A1 | CYCLOHEXYL ACID TRIAZOLE AZINES AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | SMN1; SMN2 4323/4885ALDH1A1 2244/4885L3MBTL1 4166/4885 |
| US-20130261111-A1 | TETRAHYDROPYRROLOTHIAZINE COMPOUNDS | HRH4, HRH3, HRH1 | SMN1; SMN2 4553/4885ALDH1A1 980/4885L3MBTL1 3773/4885 |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | MC2R, REN, CYP11B2 | SMN1; SMN2 1994/4885ALDH1A1 831/4885L3MBTL1 4515/4885 |
| US-20210179567-A1 | SYNTHESIS OF 1,4-DIAZASPIRO[5.5]UNDECAN-3-ONE | NDC1, SDC1, SDC2 | SMN1; SMN2 1546/4885ALDH1A1 723/4885L3MBTL1 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.